Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa.
METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods.
RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites.
CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 76 Suppl1 vom: 19. Apr., Seite S87-S96 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasumba, Irene N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Africa |
|---|
| Anmerkungen: |
Date Completed 21.04.2023 Date Revised 22.04.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac985 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35578274X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35578274X | ||
| 003 | DE-627 | ||
| 005 | 20231226065054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac985 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM35578274X | ||
| 035 | |a (NLM)37074429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasumba, Irene N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2023 | ||
| 500 | |a Date Revised 22.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Non-typhoidal Salmonella (NTS) is a common cause of gastroenteritis in young children, with limited data on NTS serovars and antimicrobial resistance in Africa | ||
| 520 | |a METHODS: We determined the prevalence of Salmonella spp. and frequency of antimicrobial resistance among serovars identified in stools of 0-59 month-old children with moderate-to-severe diarrhea (MSD) and controls enrolled in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in The Gambia, Mali, and Kenya in 2015-2018, and compared with data from the Global Enteric Multicenter Study (GEMS; 2007-2010) and the GEMS-1A study (2011). Salmonella spp. was detected by quantitative real-time PCR (qPCR) and culture-based methods. Identification of serovars was determined by microbiological methods | ||
| 520 | |a RESULTS: By qPCR, the prevalence of Salmonella spp. among MSD cases was 4.0%, 1.6%, and 1.9% and among controls was 4.6%, 2.4%, and 1.6% in The Gambia, Mali, and Kenya, respectively, during VIDA. We observed year-to-year variation in serovar distribution and variation between sites. In Kenya, Salmonella enterica serovar Typhimurium decreased (78.1% to 23.1%; P < .001) among cases and controls from 2007 to 2018, whereas serogroup O:8 increased (8.7% to 38.5%; P = .04). In The Gambia, serogroup O:7 decreased from 2007 to 2018 (36.3% to 0%; P = .001) but S. enterica serovar Enteritidis increased during VIDA (2015 to 2018; 5.9% to 50%; P = .002). Only 4 Salmonella spp. were isolated in Mali during all 3 studies. Multidrug resistance was 33.9% in Kenya and 0.8% in The Gambia across all 3 studies. Ceftriaxone resistance was only observed in Kenya (2.3%); NTS isolates were susceptible to ciprofloxacin at all sites | ||
| 520 | |a CONCLUSIONS: Understanding variability in serovar distribution will be important for the future deployment of vaccines against salmonellosis in Africa | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Salmonella | |
| 650 | 4 | |a Africa | |
| 650 | 4 | |a antibiotic resistance | |
| 650 | 4 | |a children | |
| 650 | 4 | |a diarrhea | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Powell, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Omore, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Hossain, M Jahangir |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Samba O |e verfasserin |4 aut | |
| 700 | 1 | |a Ochieng, John Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Badji, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Verani, Jennifer R |e verfasserin |4 aut | |
| 700 | 1 | |a Widdowson, Marc-Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Sen, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Nasrin, Shamima |e verfasserin |4 aut | |
| 700 | 1 | |a Permala-Booth, Jasnehta |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Roose, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Nasrin, Dilruba |e verfasserin |4 aut | |
| 700 | 1 | |a Sugerman, Ciara E |e verfasserin |4 aut | |
| 700 | 1 | |a Juma, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Awuor, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Joquina Chiquita M |e verfasserin |4 aut | |
| 700 | 1 | |a Doh, Sanogo |e verfasserin |4 aut | |
| 700 | 1 | |a Okoi, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Zaman, Syed M A |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hunsperger, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Onyango, Clayton |e verfasserin |4 aut | |
| 700 | 1 | |a Platts-Mills, James |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Houpt, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Kotloff, Karen L |e verfasserin |4 aut | |
| 700 | 1 | |a Tennant, Sharon M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 76 Suppl1 vom: 19. Apr., Seite S87-S96 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:76 Suppl1 |g day:19 |g month:04 |g pages:S87-S96 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac985 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 76 Suppl1 |b 19 |c 04 |h S87-S96 | ||